Highest-materiality recent filing
Received Nasdaq notice on Feb 11 confirming compliance with minimum bid price rule 5550(a)(2).
Nasdaq notifies 60 Degrees Pharmaceuticals of delisting for bid price rule violation
Nasdaq determined common stock failed $1.00 minimum bid price for 30 consecutive business days.
60 Degrees Pharmaceuticals to effect 1:4 reverse stock split effective Jan 20, 2026
Reverse split at 1:4 ratio effective Jan 20, 2026 at 12:01 AM ET before market open.
60 Deg Pharma closes $5M public offering, up to $10M with warrant exercise
Gross proceeds $5M from sale of 2,631,578 units (share/pre-funded warrant + warrants) at $1.90/unit.
60 Degrees Pharmaceuticals closes $1.043M registered direct offering and warrant private placement
Issued 1,021,549 shares at $1.021/share; gross proceeds ~$1.043M.
First patient enrolled in NCT06478641, an expanded access study of tafenoquine for persistent babesiosis after standard-of-care failure.
60 Degrees Pharmaceuticals raises ~$4M in private placement of common stock equivalents and warrants
Issued 2,898,551 pre-funded warrants and series A/B warrants at $1.38/share for gross proceeds of ~$4M.
60 Degrees Pharmaceuticals effects 1:12 reverse stock split to regain Nasdaq compliance
Reverse stock split at 1-for-12 ratio effective August 12, 2024; new CUSIP 83006G203.
60 Degrees Pharma shareholders approve 1:5-1:12 reverse split and 5M share increase
All five director nominees elected; each received >3.6M votes for.
60 Degrees Pharma enrolls first patient in tafenoquine babesiosis study at Tufts Medical Center
IRB approval received for open-label expanded access study of tafenoquine in immunocompromised patients with persistent babesiosis.
60 Degrees Pharmaceuticals enrolls first patient in tafenoquine babesiosis trial
First patient enrolled in randomized, double-blind, placebo-controlled trial at Tufts Medical Center.
FDA granted orphan drug designation for tafenoquine for acute babesiosis; company qualifies for market exclusivity, tax credits, and exemption from certain FDA filing fees.
60 Degrees Pharma receives Nasdaq bid price deficiency notice; 180-day cure period
Nasdaq notified SXTP that common stock failed to maintain $1.00 minimum bid price for 31 consecutive business days through Feb 27, 2024.
60 Degrees Pharmaceuticals closes $2.4M public offering of units and pre-funded units
Gross proceeds ~$2.4M; net proceeds ~$1.9M after underwriter discounts and expenses.
Following Jan 17 FDA meeting, 60 Degrees Pharma plans pivotal babesiosis study for tafenoquine
FDA Type C meeting on Jan 17, 2024 led to mutual alignment on design of pivotal study for tafenoquine in hospitalized babesiosis.
60 Degrees Pharmaceuticals regains Nasdaq minimum bid price compliance
Received Nasdaq letter on Jan 10, 2024 confirming compliance with Bid Price Rule 5550(a)(2).
60 Degrees Pharmaceuticals receives Nasdaq deficiency notice for bid price non-compliance
On Nov 2, 2023, Nasdaq notified SXTP that its common stock failed to maintain minimum $1.00 closing bid price for 30 consecutive business days through Nov 1, 2023.
60 Degrees suspends Phase IIB tafenoquine COVID-19 study; pivots to malaria and babesiosis
Company will not re-submit IND for Phase IIB study (ACLR8-LR) of tafenoquine in mild-to-moderate COVID-19 after FDA feedback made U.S. enrollment unfeasible.
Withdrew IND for ACLR8-LR Phase IIB study of tafenoquine for COVID-19 due to FDA comments on study design.
IPO of 1,415,095 units priced at $5.30/unit; each unit = 1 share + 1 tradeable warrant ($6.095 exercise) + 1 non-tradeable warrant ($6.36 exercise).
On May 13, 2026, the Board of Directors (the “Board”) of 60 Degrees Pharmaceuticals, Inc. (the “Company”) appointed Eric Francois to serve as a member of the Board, effective immediately.
Max materiality 0.90 · Median 0.55 · Most common event other_material